Form 4: Orchestra BioMed Holdings CEO David Hochman Buys Additional Shares
SEC Form 4
Orchestra BioMed Holdings CEO David Hochman reports purchasing additional shares of the company's common stock through direct and indirect holdings.
Summary
- David Hochman, CEO and Chairperson of Orchestra BioMed Holdings, Inc., has reported the purchase of additional shares of common stock.
- On September 24, 2024, Hochman directly acquired 2,500 shares at an average price of $4.91, increasing his direct holdings to 570,498 shares.
- On September 25, 2024, Hochman indirectly acquired shares through several trusts: 1,500 shares via the DPH 2008 Trust at an average price of $4.86, 2,000 shares each via the Solomon Ascher Hochman 2019 Trust, the Hannah Hochman 2019 Trust, and the Judah Herman Hochman 2019 Trust at average prices of $4.74, $4.70 and $4.73 respectively.
- Additionally, 3,140 shares were acquired indirectly through the NSH 2008 Family Trust.
- The reported transactions reflect purchases made in multiple transactions at varying prices within specified ranges.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but it's a single data point and doesn't guarantee future performance.
Positives
- The CEO's purchase of additional shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's important to consider the overall context of the company's performance and industry trends.
Comparison to Industry Standards
- Comparing insider trading activity at Orchestra BioMed to similar companies in the medical device or biotechnology sectors could provide insights.
- For example, comparing the percentage of shares purchased by insiders relative to the company's market capitalization against companies like Medtronic or Boston Scientific could be informative.
- Analyzing the timing of these purchases relative to major company announcements or industry events would also be relevant.
Stakeholder Impact
- The CEO's stock purchases could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/24/2024 | David Hochman directly purchased 2,500 shares of common stock. |
| 09/25/2024 | David Hochman indirectly purchased shares through several trusts. |
| 09/26/2024 | Date of signature for the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.